m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00399)
Name
Bis-(5-hydroxy-1H-indol-2-yl)-methanone
Synonyms
Flt-3 Inhibitor II; 896138-40-2; CHEMBL377193; Bis-(5-hydroxy-1H-indol-2-yl)methanone; Bis(5-hydroxy-1H-indol-2-yl)methanone; SCHEMBL2230377; GTPL5971; CTK8F1061; DTXSID40469293; HMS3229E09; IN1480; BDBM50187351; AKOS028113701; CCG-206752; RT-012728; Flt-3 inhibitor II
    Click to Show/Hide
Status
Investigative
Structure
Formula
C17H12N2O3
InChI
1S/C17H12N2O3/c20-11-1-3-13-9(5-11)7-15(18-13)17(22)16-8-10-6-12(21)2-4-14(10)19-16/h1-8,18-21H
InChIKey
NIMIWWQLOGNYHD-UHFFFAOYSA-N
PubChem CID
11601743
TTD Drug ID
D0I3XZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Platelet-derived growth factor receptor alpha (PDGFRA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor alpha (PDGFRA) is a therapeutic target for Bis-(5-hydroxy-1H-indol-2-yl)-methanone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Bis-(5-hydroxy-1H-indol-2-yl)-methanone through regulating the expression of Platelet-derived growth factor receptor alpha (PDGFRA). [1], [2]
Platelet-derived growth factor receptor beta (PDGFRB)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Platelet-derived growth factor receptor beta (PDGFRB) is a therapeutic target for Bis-(5-hydroxy-1H-indol-2-yl)-methanone. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Bis-(5-hydroxy-1H-indol-2-yl)-methanone through regulating the expression of Platelet-derived growth factor receptor beta (PDGFRB). [3], [4]
References
Ref 1 METTL3-mediated N (6)-methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics. 2022 Jan 1;12(1):277-289. doi: 10.7150/thno.63441. eCollection 2022.
Ref 2 Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. doi: 10.1021/jm058033i.
Ref 3 Mutant NPM1-Regulated FTO-Mediated m(6)A Demethylation Promotes Leukemic Cell Survival via PDGFRB/ERK Signaling Axis. Front Oncol. 2022 Feb 8;12:817584. doi: 10.3389/fonc.2022.817584. eCollection 2022.
Ref 4 Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem. 2003 Aug 29;278(35):32892-8. doi: 10.1074/jbc.M210405200. Epub 2003 Jun 18.